secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001157523-23-001677
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q3 revenue up 7% to $3.9B, raises FY revenue guidance to $15.1-$15.5B
--------------------------------------------------------------------------

- Revenue $3.85B (+7% YoY); GAAP EPS $0.07, non-GAAP EPS $0.60.
- Raised 2023 revenue outlook to $15.1-$15.5B from $15.0-$15.4B; reaffirms non-GAAP EPS $2.25-$2.55.
- AUSTEDO and AJOVY drove growth; global generics revenues increased across all segments.
- Entered exclusive collaboration with Sanofi on Anti TL1-A (TEV-'574) in October 2023.
- Appointed Dr. R. Ananthanarayanan as CEO of Teva api; olanzapine LAI Phase 3 results now H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752323001677/0001157523-23-001677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752323001677/a53780340.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer